Company intelligence / Profile preview
Niagen Bioscience
- Ownership
- Public · NAGE
- Employees
- ~119
- Development stage
- Other
Overview
Niagen Bioscience’s flagship product Niagen® has been the subject of over 35 human clinical studies and more than 400 published scientific studies. Clinical results show that supplementation with nicotinamide riboside chloride safely and effectively increases NAD+ levels in humans. Tru Niagen®, the company’s consumer product line featuring this ingredient, has sold over eight million bottles globally. The company also recently launched pharmaceutical-grade injectable/IV forms for clinical use.
- Therapeutic areas
- NeurologyMetabolic DisordersOther
- Modalities
- Small molecule (nicotinamide riboside chloride)Dietary supplement ingredient (nutraceutical)Pharmaceutical ingredient (for IV/injectable use)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Niagen Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Niagen Bioscience.